GR3029632T3 - A novel biologically active peptide derived from frog (frog CNP) - Google Patents

A novel biologically active peptide derived from frog (frog CNP)

Info

Publication number
GR3029632T3
GR3029632T3 GR990400722T GR990400722T GR3029632T3 GR 3029632 T3 GR3029632 T3 GR 3029632T3 GR 990400722 T GR990400722 T GR 990400722T GR 990400722 T GR990400722 T GR 990400722T GR 3029632 T3 GR3029632 T3 GR 3029632T3
Authority
GR
Greece
Prior art keywords
frog
biologically active
cnp
active peptide
peptide derived
Prior art date
Application number
GR990400722T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Suntory Ltd
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd, Hisayuki Matsuo filed Critical Suntory Ltd
Publication of GR3029632T3 publication Critical patent/GR3029632T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
GR990400722T 1990-09-07 1999-03-09 A novel biologically active peptide derived from frog (frog CNP) GR3029632T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238294A JP2977159B2 (ja) 1990-09-07 1990-09-07 カエル由来新規生理活性ペプチド（カエルｃｎｐ）

Publications (1)

Publication Number Publication Date
GR3029632T3 true GR3029632T3 (en) 1999-06-30

Family

ID=17028056

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990400722T GR3029632T3 (en) 1990-09-07 1999-03-09 A novel biologically active peptide derived from frog (frog CNP)

Country Status (8)

Country Link
US (1) US5336759A (el)
EP (1) EP0475290B1 (el)
JP (1) JP2977159B2 (el)
AT (1) ATE175211T1 (el)
DE (1) DE69130695T2 (el)
DK (1) DK0475290T3 (el)
ES (1) ES2127189T3 (el)
GR (1) GR3029632T3 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP4825667B2 (ja) 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
JP4972403B2 (ja) 2004-03-31 2012-07-11 一和 中尾 身長増加用組成物
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
JP2010539059A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 例えばＡＩＤＳまたはアルツハイマーの治療のための治療剤としてのβ−メラノトロピンの使用
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CN107405390A (zh) 2014-12-05 2017-11-28 阿雷克森制药公司 用重组碱性磷酸酶治疗癫痫
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
WO2017031114A1 (en) 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
BR112019020506A2 (pt) 2017-03-31 2020-08-04 Alexion Pharmaceuticals, Inc. métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
JPH04120095A (ja) 1992-04-21
EP0475290B1 (en) 1998-12-30
DE69130695T2 (de) 1999-06-10
ATE175211T1 (de) 1999-01-15
DE69130695D1 (de) 1999-02-11
JP2977159B2 (ja) 1999-11-10
DK0475290T3 (da) 1999-08-30
US5336759A (en) 1994-08-09
ES2127189T3 (es) 1999-04-16
EP0475290A1 (en) 1992-03-18

Similar Documents

Publication Publication Date Title
GR3029632T3 (en) A novel biologically active peptide derived from frog (frog CNP)
GR3029628T3 (en) A novel biologically active peptide derived from chicken (chicken CNP)
PT1538202E (pt) Produção de alga-galactosidase a humana
IL111843A0 (en) Preparation of 3,4,4-trisubstituted-piperidinyl-n-alkylcarboxylates and intermediates
FI870113A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4,5,6-substioitujenN-(substituoitu-fenyyli)-2-pyrimidiiniamiinien valmistamiseksi
SE8505011D0 (sv) Production of aminoethylethanolamine using rare earth metal or strontium hydrogen phosphates as catalysts
EP0317627A4 (en) Oncogene-encoded polypeptide having growth factor activity and methods of production and use thereof
HUT51295A (en) Process for producing peptidalcohol derivatives of anticoagulant activity
ES2124694T3 (es) Clonacion de la n-metil-hidantoinasa.
EP0486067A3 (en) Peroxidase gene of microbial origin
NZ238331A (en) Peptide with peptidylhydroxyglycine n-c lyase activity, dna encoding it and its preparation and its use
DE3565525D1 (en) Process for the preparation of monochloroacetic acid from glycolic acid
PT82322A (en) Process for preparing cycloalkanecarboxanilides
EP0316907A3 (en) Enzyme inhibitor and method of producing the same
EP1295943A4 (en) POLYPEPTIDES CAPABLE THE POWER TO STIMULATE NEUTROPHILES
DE59904211D1 (de) Verfahren zur Reinigung und Isolierung von 2,3,5-Trimethyl-p-benzochinon
LTIP1501A (en) Using of known combination for treatment of rejection reaction by transplantation of organs
IL83118A (en) N-acylated-n)- alkylcarbothioic acid hydrazides
EP0259084A3 (en) Crystalline n-(s-3-methylheptanoyl)-d-gamma-glutamyl-glycyl-d-alanine, and processes and intermediates therefor
SE8403252L (sv) Forfarande vid forbrenning, jemte brensle
UA23007A1 (uk) 9-метокси-10-етил-12h-хромено[3',2'-3,4]піроло[1,2-а]-хінолін-12-oh, що володіє аналептичною дією та спосіб його отримання